United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Burney Co.

Burney Co. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,664 shares of the biotechnology company’s stock after selling 172 shares during the quarter. Burney Co.’s holdings in United Therapeutics were worth $2,133,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of UTHR. BI Asset Management Fondsmaeglerselskab A S lifted its stake in United Therapeutics by 204.1% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,302 shares of the biotechnology company’s stock valued at $740,000 after buying an additional 2,216 shares in the last quarter. Pictet Asset Management SA grew its position in United Therapeutics by 1.3% during the 1st quarter. Pictet Asset Management SA now owns 288,418 shares of the biotechnology company’s stock worth $64,594,000 after purchasing an additional 3,766 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in United Therapeutics by 9.5% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 32,157 shares of the biotechnology company’s stock valued at $7,063,000 after purchasing an additional 2,797 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of United Therapeutics by 4.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,846 shares of the biotechnology company’s stock valued at $849,000 after purchasing an additional 152 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of United Therapeutics by 6.2% in the second quarter. KBC Group NV now owns 820 shares of the biotechnology company’s stock worth $181,000 after buying an additional 48 shares during the period. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on UTHR. JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $290.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, August 3rd. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $256.00 to $268.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 10th. Finally, Wedbush reissued an “outperform” rating and issued a $308.00 price target (up previously from $307.00) on shares of United Therapeutics in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $288.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 383 shares of United Therapeutics stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $222.36, for a total transaction of $85,163.88. Following the completion of the transaction, the director now directly owns 6,303 shares of the company’s stock, valued at $1,401,535.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $222.19, for a total value of $1,333,140.00. Following the transaction, the executive vice president now owns 36,599 shares of the company’s stock, valued at approximately $8,131,931.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 383 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $222.36, for a total transaction of $85,163.88. Following the sale, the director now directly owns 6,303 shares of the company’s stock, valued at $1,401,535.08. The disclosure for this sale can be found here. Insiders have sold 30,383 shares of company stock worth $6,806,244 over the last three months. Company insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 0.4 %

UTHR stock opened at $229.26 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.65 and a quick ratio of 4.51. The company has a 50-day moving average of $225.96 and a two-hundred day moving average of $225.86. The stock has a market capitalization of $10.77 billion, a price-to-earnings ratio of 12.63 and a beta of 0.57. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $283.09.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $5.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.28. United Therapeutics had a net margin of 40.82% and a return on equity of 17.10%. The business had revenue of $609.40 million for the quarter, compared to the consensus estimate of $585.82 million. During the same quarter last year, the company posted $4.91 earnings per share. United Therapeutics’s quarterly revenue was up 18.1% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Co. will post 19.36 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.